-
1.
公开(公告)号:US09718766B2
公开(公告)日:2017-08-01
申请号:US14854616
申请日:2015-09-15
发明人: Chongxi Yu , Lina Xu
IPC分类号: A61K31/195 , C07C219/06 , C07C317/44 , A61K31/137 , C07C229/36 , A61K31/198 , A61K31/277 , C07C271/16 , C07C271/22 , C07D321/12 , C07C219/10 , C07C219/14 , C07C219/28 , C07C229/12 , C07C327/30 , C07C229/58 , C07D455/02 , C07D471/04 , C07C237/06 , C07C237/20 , C07D207/16 , C07K5/083 , C07D211/62 , C07K5/097 , A61K31/197 , A61K31/24 , A61K31/40 , C07C219/32 , C07C237/08 , C07C327/36
CPC分类号: C07D471/04 , A61K31/137 , A61K31/195 , A61K31/197 , A61K31/198 , A61K31/24 , A61K31/277 , A61K31/40 , C07C217/60 , C07C219/06 , C07C219/10 , C07C219/14 , C07C219/28 , C07C219/32 , C07C229/12 , C07C229/36 , C07C229/58 , C07C237/06 , C07C237/08 , C07C237/20 , C07C271/16 , C07C271/22 , C07C317/44 , C07C327/30 , C07C327/36 , C07C2602/08 , C07D207/16 , C07D211/62 , C07D321/12 , C07D455/02 , C07K5/0806 , C07K5/0823 , A61K2300/00
摘要: One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
-
2.
公开(公告)号:US11685739B2
公开(公告)日:2023-06-27
申请号:US17396975
申请日:2021-08-09
发明人: Chongxi Yu , Lina Xu
IPC分类号: C07D471/04 , C07C271/16 , C07C271/22 , C07D321/12 , C07C219/10 , C07C219/14 , C07C219/28 , C07C229/12 , C07C327/30 , C07C229/58 , C07D455/02 , C07C237/06 , C07C237/20 , C07D207/16 , C07K5/083 , C07D211/62 , C07K5/097 , A61K31/137 , C07C229/36 , A61K31/195 , A61K31/198 , A61K31/277 , C07C317/44 , A61K31/197 , A61K31/24 , A61K31/40 , C07C219/06 , C07C219/32 , C07C237/08 , C07C327/36 , C07C217/60
CPC分类号: C07D471/04 , A61K31/137 , A61K31/195 , A61K31/197 , A61K31/198 , A61K31/24 , A61K31/277 , A61K31/40 , C07C217/60 , C07C219/06 , C07C219/10 , C07C219/14 , C07C219/28 , C07C219/32 , C07C229/12 , C07C229/36 , C07C229/58 , C07C237/06 , C07C237/08 , C07C237/20 , C07C271/16 , C07C271/22 , C07C317/44 , C07C327/30 , C07C327/36 , C07D207/16 , C07D211/62 , C07D321/12 , C07D455/02 , C07K5/0806 , C07K5/0823 , C07C2602/08 , A61K31/198 , A61K2300/00 , A61K31/195 , A61K2300/00 , A61K31/137 , A61K2300/00 , A61K31/277 , A61K2300/00
摘要: One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
-
3.
公开(公告)号:US20230130980A1
公开(公告)日:2023-04-27
申请号:US18051060
申请日:2022-10-31
发明人: Chongxi Yu , Lina Xu , Yuhua Chen , Binbing Yan , Shiqian Tu
IPC分类号: C07D499/21
摘要: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
-
公开(公告)号:US11479527B2
公开(公告)日:2022-10-25
申请号:US16209744
申请日:2018-12-04
发明人: Chongxi Yu , Lina Xu
IPC分类号: C07C233/47 , C07C229/42 , C07F9/24
摘要: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of mustards and mustard-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
-
5.
公开(公告)号:US20220064157A1
公开(公告)日:2022-03-03
申请号:US17396975
申请日:2021-08-09
发明人: Chongxi Yu , Lina Xu
IPC分类号: C07D471/04 , C07C271/16 , C07C271/22 , C07D321/12 , C07C219/10 , C07C219/14 , C07C219/28 , C07C229/12 , C07C327/30 , C07C229/58 , C07D455/02 , C07C237/06 , C07C237/20 , C07D207/16 , C07K5/083 , C07D211/62 , C07K5/097 , A61K31/137 , C07C229/36 , A61K31/195 , A61K31/198 , A61K31/277 , C07C317/44 , A61K31/197 , A61K31/24 , A61K31/40 , C07C219/06 , C07C219/32 , C07C237/08 , C07C327/36 , C07C217/60
摘要: One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
-
6.
公开(公告)号:US20240131017A1
公开(公告)日:2024-04-25
申请号:US18400716
申请日:2023-12-29
发明人: Chongxi Yu , Lina Xu
IPC分类号: A61K31/4545 , A61K31/135 , A61K31/381 , A61K31/43 , A61K31/445 , A61K31/47 , A61K31/625 , A61K45/06 , A61K47/54
CPC分类号: A61K31/4545 , A61K31/135 , A61K31/381 , A61K31/43 , A61K31/445 , A61K31/47 , A61K31/625 , A61K45/06 , A61K47/54
摘要: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
-
7.
公开(公告)号:US11485744B2
公开(公告)日:2022-11-01
申请号:US15947983
申请日:2018-04-09
发明人: Chongxi Yu , Lina Xu , Yuhua Chen , Binbing Yan , Shiqian Tu
IPC分类号: C07D499/21
摘要: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
-
公开(公告)号:US20220096370A1
公开(公告)日:2022-03-31
申请号:US17493321
申请日:2021-10-04
发明人: Chongxi Yu , Lina Xu
IPC分类号: A61K9/00 , C07C233/25 , A61K31/22 , C07C231/12 , A61K47/54 , A61K9/70 , A61K31/167 , A61K31/612
摘要: The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for 4-aminophenol derivatives, which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate.
-
9.
公开(公告)号:US20240115562A1
公开(公告)日:2024-04-11
申请号:US18507797
申请日:2023-11-13
发明人: Chongxi Yu , Lina Xu
IPC分类号: A61K31/4545 , A61K31/135 , A61K31/381 , A61K31/43 , A61K31/445 , A61K31/47 , A61K31/625 , A61K45/06 , A61K47/54
CPC分类号: A61K31/4545 , A61K31/135 , A61K31/381 , A61K31/43 , A61K31/445 , A61K31/47 , A61K31/625 , A61K45/06 , A61K47/54
摘要: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.
-
10.
公开(公告)号:US20240024273A1
公开(公告)日:2024-01-25
申请号:US18251336
申请日:2021-06-04
发明人: Chongxi Yu , Lina Xu
IPC分类号: A61K31/222 , A61K9/00 , A61P19/02 , A61P29/00
CPC分类号: A61K31/222 , A61K9/0014 , A61P19/02 , A61P29/00
摘要: Provided herein is 2-(diethylamino) ethyl 2-(4-isobutylphenyl) propionate or pharmaceutically acceptable salts thereof. Furthermore, for use and methods in the treatment of various pains and inflammation, in particular osteoarthritis with pharmaceutical compositions, treatment kits and devices comprising 2-(diethylamino) ethyl 2-(4-isobutylphenyl) propionate and/or pharmaceutically acceptable salts thereof, as well as dosage forms, dosages, and methods of use thereof through topical administration, for treatment of various pains and inflammation, in particular osteoarthritis, are disclosed.
-
-
-
-
-
-
-
-
-